Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer


Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, discusses ​the final overall survival (OS) results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor (HR)–positive​, HER2-negative metastatic breast cancer.

​Patients were randomized 1:1:1 to receive the combination of abemaciclib (Verzenio) ​and tamoxifen, 150 mg of abemaciclib monotherapy, or 200 mg of abemaciclib plus prophylactic loperamide, says Hamilton.

However, investigators reported an OS benefit in patients who received the combination of tamoxifen and abemaciclib versus 200 mg of abemaciclib monotherapy. The median OS was 24​.2 months versus 17 months, respectively.

These findings are encouraging, especially for patients with metastatic disease who did not receive CDK4​/6 inhibitors in addition to those who do ​not tolerate endocrine therapy ​well, Hamilton concludes.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD